Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Article category

Page Path

HOME
ARTICLE CATEGORY
Article category

Review

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 3397 Download: 200 Web of Science: 8 Crossref: 11

Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management

Anja Geerts, Sander Lefere

Clin Mol Hepatol. 2023;29(Suppl):S276-S285. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0373

View: 3755 Download: 139 Web of Science: 5 Crossref: 5

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease

Hyunwoo Oh, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2023;29(Suppl):S261-S267. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0393

View: 3346 Download: 115 Web of Science: 5 Crossref: 5

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 6963 Download: 497 Web of Science: 33 Crossref: 36

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra

Clin Mol Hepatol. 2023;29(Suppl):S286-S301. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0392

View: 5775 Download: 255 Web of Science: 13 Crossref: 15

Nonalcoholic fatty liver disease and non-liver comorbidities

Richie Manikat, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(Suppl):s86-s102. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0442

View: 5136 Download: 207 Web of Science: 8 Crossref: 9

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 3897 Download: 227 Web of Science: 7 Crossref: 8

Preface

Yoon Jun Kim

Clin Mol Hepatol. 2023;29(Suppl):S2-S2. Published online February 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0011

View: 1971 Download: 39

Preface

Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S3-S3. Published online February 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0014

View: 1976 Download: 45

Congratulatory remarks

Si Hyun Bae

Clin Mol Hepatol. 2023;29(Suppl):S1-S1. Published online February 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0027

View: 2154 Download: 52

Snapshot

Epidemiology and updated management for autoimmune liver disease

Nae-Yun Heo, Haeryoung Kim

Clin Mol Hepatol. 2023;29(1):194-196. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0387

View: 4554 Download: 154 Web of Science: 5 Crossref: 6

Correspondence

Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”

Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):191-193. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0410

View: 2785 Download: 64

Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”

Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani

Clin Mol Hepatol. 2023;29(1):188-190. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0408

View: 3165 Download: 64 Web of Science: 2 Crossref: 2

Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations”

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2023;29(1):185-187. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0375

View: 2683 Download: 39

Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”

Won Sohn, Yong-Han Paik

Clin Mol Hepatol. 2023;29(1):182-184. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0411

View: 2884 Download: 47

Letter to the Editor

Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”

Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn

Clin Mol Hepatol. 2023;29(1):179-181. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0409

View: 2764 Download: 46 Web of Science: 1 Crossref: 1

Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”

Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen

Clin Mol Hepatol. 2023;29(1):176-178. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0377

View: 2732 Download: 51

Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”

Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim

Clin Mol Hepatol. 2023;29(1):173-175. Published online November 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0372

View: 2838 Download: 44 Web of Science: 1 Crossref: 1

Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Seung Min Lee, Dae Won Jun

Clin Mol Hepatol. 2023;29(1):171-172. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0381

View: 2793 Download: 56

Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults”

Hye Won Lee

Clin Mol Hepatol. 2023;29(1):169-170. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0384

View: 3016 Download: 50 Web of Science: 1 Crossref: 1

Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”

Rujittika Mungmunpuntipantip, Viroj Wiwanitkit

Clin Mol Hepatol. 2023;29(1):168. Published online October 31, 2022

DOI: https://doi.org/10.3350/cmh.2022.0328

View: 2839 Download: 53 Web of Science: 1 Crossref: 1

Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”

Do Seon Song, U Im Chang, Jin Mo Yang

Clin Mol Hepatol. 2023;29(1):165-167. Published online October 31, 2022

DOI: https://doi.org/10.3350/cmh.2022.0339

View: 3340 Download: 61 Web of Science: 1 Crossref: 1

Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Yuanbin Liu, Mingkai Chen

Clin Mol Hepatol. 2023;29(1):163-164. Published online October 27, 2022

DOI: https://doi.org/10.3350/cmh.2022.0326

View: 3167 Download: 61 Web of Science: 1 Crossref: 1

Original Article

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):146-162. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0172

View: 5721 Download: 227 Web of Science: 11 Crossref: 11

Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients

Yu Jun Wong, Chen Zhaojin, Guilia Tosetti, Elisabetta Degasperi, Sanchit Sharma, Samagra Agarwal, Liu Chuan, Chan Yiong Huak, Li Jia, Qi Xiaolong, Anoop Saraya, Massimo Primignani

Clin Mol Hepatol. 2023;29(1):135-145. Published online September 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0181

View: 6236 Download: 348 Web of Science: 18 Crossref: 21

Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly

Young Eun Chon, Seong Yong Park, Han Pyo Hong, Donghee Son, Jonghyun Lee, Eileen Yoon, Soon Sun Kim, Sang Bong Ahn, Soung Won Jeong, Dae Won Jun

Clin Mol Hepatol. 2023;29(1):120-134. Published online August 12, 2022

DOI: https://doi.org/10.3350/cmh.2021.0395

View: 4657 Download: 210 Web of Science: 18 Crossref: 17

Editorial

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?

Young-Suk Lim

Clin Mol Hepatol. 2023;29(1):118-119. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0413

View: 3295 Download: 177 Web of Science: 2 Crossref: 2

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers

Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2023;29(1):113-117. Published online October 31, 2022

DOI: https://doi.org/10.3350/cmh.2022.0333

View: 3098 Download: 99 Web of Science: 3 Crossref: 4

Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey

Susana G Rodrigues

Clin Mol Hepatol. 2023;29(1):110-112. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0414

View: 3542 Download: 101 Web of Science: 2 Crossref: 2

Non-invasive tests-based risk stratification: Baveno VII and beyond

Georg Semmler, Mathias Jachs, Mattias Mandorfer

Clin Mol Hepatol. 2023;29(1):105-109. Published online November 23, 2022

DOI: https://doi.org/10.3350/cmh.2022.0361

View: 3954 Download: 134 Web of Science: 6 Crossref: 7

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

14.0
First decision

09 Days

Publication after acceptance

03 Days

*Last 12 months

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5405	MAFLD: How is it different from NAFLD?
Viewed By 5214	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5094	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4725	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach